Fair D S, Plow E F, Edgington T S
J Clin Invest. 1979 Oct;64(4):884-94. doi: 10.1172/JCI109554.
Human Factor X was isolated from Cohn fraction III and characterized by polyacrylamide gel electrophoresis, amino acid composition, and isoelectric focusing. Two molecular forms with biological activity were observed at isoelectric points of 4.8 and 5.0. Antisera generated to Factor X was monospecific and used to establish an equilibrium competitive inhibition radioimmunoassay. This assay was specific for human Factor X and did not cross-react with human prothrombin or bovine Factor X within the sensitivity range of 6-300 ng Factor X antigen/ml. The mean concentration of Factor X based on the antigen was 11.9 mug/ml, whereas concentration values based on coagulant activity was 7.8 mug/ml. This 30% difference in measurement appears to result from the presence of a subpopulation of Factor X molecules devoid of coagulant activity. The radioimmunoassay was used to qualitatively and quantitatively compare purified Factor X to plasmic Factor X obtained from normal, warfarintreated, acquired Factor X-deficient, and congenitaldeficient patients. In all but one case, the Factor X present in these plasmas was immunochemically identical to the purified Factor X and permitted precise quantitation of these abnormal Factor X molecules. Factor X procoagulant activity was analyzed relative to Factor X antigen and the specific activities were used to characterize normal and abnormal Factor X molecules. Reduced Factor X activity in plasmas from warfarin-treated and acquired Factor X-deficient patients was attributed to both decreases in Factor X antigen and decreased function of the Factor X molecules. Congenitally deficient patients, in general, showed a reduction in Factor X antigen in parallel with Factor X procoagulant activities resulting from comparable decreases in specific biological activity of the molecules.
人凝血因子X从Cohn III组分中分离出来,并通过聚丙烯酰胺凝胶电泳、氨基酸组成分析和等电聚焦进行表征。在等电点4.8和5.0处观察到两种具有生物活性的分子形式。针对凝血因子X产生的抗血清具有单特异性,并用于建立平衡竞争性抑制放射免疫测定法。该测定法对人凝血因子X具有特异性,在6 - 300 ng因子X抗原/ml的灵敏度范围内,与人凝血酶原或牛凝血因子X无交叉反应。基于抗原的凝血因子X平均浓度为11.9 μg/ml,而基于凝血活性的浓度值为7.8 μg/ml。这种30%的测量差异似乎是由于存在缺乏凝血活性的凝血因子X分子亚群所致。放射免疫测定法用于定性和定量比较纯化的凝血因子X与从正常、接受华法林治疗、获得性凝血因子X缺乏和先天性缺乏患者获得的血浆凝血因子X。除1例病例外,这些血浆中存在的凝血因子X在免疫化学上与纯化的凝血因子X相同,并允许对这些异常凝血因子X分子进行精确定量。相对于凝血因子X抗原分析了凝血因子X促凝活性,并使用比活性来表征正常和异常凝血因子X分子。华法林治疗和获得性凝血因子X缺乏患者血浆中凝血因子X活性降低归因于凝血因子X抗原的减少和凝血因子X分子功能的降低。一般来说,先天性缺乏患者的凝血因子X抗原减少与凝血因子X促凝活性降低平行,这是由于分子的特定生物活性可比降低所致。